Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) – Stock analysts at Oppenheimer lowered their FY2019 EPS estimates for shares of Madrigal Pharmaceuticals in a report issued on Wednesday, November 6th, according to Zacks Investment Research. Oppenheimer analyst J. Olson now forecasts that the biopharmaceutical company will post earnings per share of ($5.39) for the year, down from their prior estimate of ($4.86). Oppenheimer also issued estimates for Madrigal Pharmaceuticals’ Q4 2019 earnings at ($1.74) EPS, FY2020 earnings at ($6.46) EPS, FY2021 earnings at ($7.55) EPS, FY2022 earnings at ($3.43) EPS and FY2023 earnings at $2.61 EPS.
Several other research firms also recently weighed in on MDGL. Cowen restated a “buy” rating on shares of Madrigal Pharmaceuticals in a research note on Tuesday, November 12th. Zacks Investment Research downgraded Madrigal Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 9th. HC Wainwright lowered their target price on Madrigal Pharmaceuticals from $225.00 to $215.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. ValuEngine upgraded Madrigal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, October 29th. Finally, BidaskClub upgraded Madrigal Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $161.13.
MDGL stock opened at $110.41 on Monday. Madrigal Pharmaceuticals has a 1-year low of $82.31 and a 1-year high of $148.18. The company has a market capitalization of $1.67 billion, a price-to-earnings ratio of -49.73 and a beta of 1.11. The business has a 50 day simple moving average of $95.47 and a two-hundred day simple moving average of $95.44.
Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.42) by $0.03. During the same period in the prior year, the company earned ($0.56) earnings per share.
Several hedge funds and other institutional investors have recently bought and sold shares of MDGL. Tower Research Capital LLC TRC purchased a new stake in Madrigal Pharmaceuticals during the 3rd quarter valued at $41,000. Captrust Financial Advisors purchased a new stake in Madrigal Pharmaceuticals during the 2nd quarter valued at $163,000. Los Angeles Capital Management & Equity Research Inc. purchased a new stake in Madrigal Pharmaceuticals during the 2nd quarter valued at $215,000. Stanley Laman Group Ltd. purchased a new stake in Madrigal Pharmaceuticals during the 2nd quarter valued at $256,000. Finally, Jane Street Group LLC raised its holdings in Madrigal Pharmaceuticals by 7.8% during the 2nd quarter. Jane Street Group LLC now owns 2,523 shares of the biopharmaceutical company’s stock valued at $265,000 after buying an additional 183 shares during the period. Hedge funds and other institutional investors own 62.15% of the company’s stock.
Madrigal Pharmaceuticals Company Profile
Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company’s lead candidate is MGL-3196, an orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) ß-selective agonist, which is in Phase II clinical trials for the treatment of non-alcoholic steatohepatitis and heterozygous familial hypercholesterolemia.
Recommended Story: What is the Dividend Aristocrat Index?
Get a free copy of the Zacks research report on Madrigal Pharmaceuticals (MDGL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Madrigal Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.
